The ORIENT-32 study (NCT03794440) is a randomized, open-label, multicenter trial in China that will compare sintilimab (anti-PD1 mAb) and bevacizumab (anti-VEGF mAb) vs. sorafenib as a first-line treatment in patients with advanced HCC [74]. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.